Senators grilled Novo Nordisk CEO Lars Jorgensen at a hearing on Tuesday about the cost of diabetes drug Ozempic and weight loss medication Wegovy, both of which are often prohibitively expensive in the United States despite their life-saving potential.

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy, on Tuesday, Sen. Bernie Sanders alleged that 40,000 people a year in the US could die if the company doesn’t make the medicines more affordable.